Saturday 17 October 2026 Export CPIX’s income statement to Excel — free account

Cumberland Pharmaceuticals Inc.

CPIX Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue fell 56.3%, EPS fell 440.0%, free cash flow fell 82.8% and total debt was flat, each against the same quarter a year earlier.

7.18 0.36 −4.77%

Follow CPIX

Alert me

Market cap: $113.0M
P/E: 0.0×
Fwd P/E: −12.2×
Dividend yield: 0.00%
F-score: 6/9
Altman Z: 0.65
Beneish M: −2.58
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 41.60%

Capital & Financial Ratios $m

Market Cap 112.97

Revenue 41.73

Net Income (10.94)

Free Cash Flow 0.58

Net Debt (3.86)

Current Ratio 0.96

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (12.20)

P/S ratio 2.58

P/B ratio 6.29

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth 24.77%

Next 5Y EPS Growth 30.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 75.93%

10-year low 10-year high

P/B against its own 10 years 98.64%

10-year low 10-year high

EV/Sales against its own 10 years 95.61%

10-year low 10-year high

EV/FCF against its own 10 years 95.04%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 0.00

Annual Dividend Yield 0.00%

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	18	18	11	4
Receivables	10	12	17	13
Inventory	5	4	6	0
Other	—	—	—	—
	36	36	37	34

	2023	2024	2025	Q'26
Payables	14	14	19	20
ST’ Debt	—	5	—	—
Other	14	12	18	2
	28	32	37	35

Compound Annual Growth %

	10y	5y	3y
Sales	2.88%	3.52%	1.95%
Cash Flow	(1.74%)	(1.85%)	(16.44%)
Earnings	0.00%	0.00%	0.00%
Book Value	(10.78%)	(12.14%)	(11.97%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	9	0	—	—	—
’25	12	0	8	24	45
’24	8	10	9	10	38
’23	9	11	10	9	40
’22	11	10	11	9	42
’21	11	9	8	8	36
’20	8	10	9	10	37

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	4	1	0	0	5
’24	(2)	(1)	0	2	(1)
’23	(1)	5	1	1	6
’22	0	2	3	4	8
’21	2	3	0	2	6
’20	1	3	1	1	5

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	4	1	0	0	5
’24	(2)	(1)	0	2	(1)
’23	(2)	5	1	1	6
’22	0	2	2	2	6
’21	2	3	0	2	6
’20	0	3	0	1	3

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.22)	(0.27)	—	—	—
’25	0.08	(0.05)	(0.13)	(0.09)	(0.19)
’24	(0.14)	(0.08)	(0.11)	(0.14)	(0.46)
’23	0.01	0.06	(0.07)	(0.44)	(0.44)
’22	(0.09)	(0.09)	(0.03)	(0.17)	(0.38)
’21	0.01	0.08	(0.07)	(0.26)	(0.24)
’20	(0.07)	(0.06)	(0.03)	(0.06)	(0.22)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4.20	5.28	5.06	4.19	2.77	2.20	1.89	1.43	1.04	1.85	Analyst estimates 2026–2028 Powerpack
	High	6.00	7.96	7.45	6.99	5.44	7.51	5.65	2.91	3.05	7.25
People
People	Employees	82	84	80	94	90	83	85	91	91	93
	Revenue/emp, $m	0.40	0.49	0.37	0.37	0.42	0.43	0.49	0.43	0.42	0.48
Income, $m
Income, $m	Revenue	33	41	29	34	37	36	42	40	38	45
	Gross margin, %	81.96	82.09	79.50	78.42	76.89	75.51	78.29	84.66	82.61	85.02
	EBT	(1)	(4)	(11)	(9)	(7)	(6)	(6)	(6)	(6)	(3)
	EBT margin, %	(4.04)	(9.42)	(36.82)	(27.02)	(17.55)	(15.46)	(13.29)	(15.89)	(17.08)	(6.31)
	Net income	(1)	(8)	(7)	(4)	(3)	(4)	(6)	(6)	(6)	(3)
	Depreciation	2	3	3	4	5	5	5	8	5	4
Per share, $
Per share, $	Revenue	2.03	2.59	1.88	2.23	2.47	2.41	2.88	2.77	2.69	3.00
	Earnings	(0.06)	(0.50)	(0.45)	(0.23)	(0.22)	(0.24)	(0.38)	(0.44)	(0.46)	(0.19)
	Cash flow	0.04	(0.03)	0.20	0.20	0.36	0.43	0.58	0.43	(0.04)	0.33
	Capex	(0.13)	(0.09)	(0.27)	(0.07)	(0.14)	(0.02)	(0.14)	(0.03)	(0.01)	(0.01)
	Free cash flow	(0.10)	(0.13)	(0.07)	0.13	0.22	0.40	0.44	0.39	(0.06)	0.32
	Book value	4.50	4.02	3.56	3.32	3.09	2.86	2.47	2.05	1.60	1.65
	Shares, m	16	16	16	15	15	15	15	14	14	15
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	2.88	2.73	3.21	2.31	1.19	1.93	0.80	0.67	0.88	1.33
	P/B	1.30	1.76	1.69	1.55	0.95	1.63	0.94	0.90	1.48	2.41
	EV/Sales	1.49	1.75	2.66	2.05	0.96	1.63	0.72	0.54	0.81	1.30
	EV/FCF	(31.45)	(35.13)	(67.04)	34.60	10.90	9.78	4.74	3.77	(38.68)	12.21
Cash, $m
Cash, $m	Operating cash flow	1	(1)	3	3	5	6	8	6	(1)	5
	Capex	(2)	(1)	(4)	(1)	(2)	0	(2)	0	0	0
	Free cash flow	(2)	(2)	(1)	2	3	6	6	6	(1)	5
Balance, $m
Balance, $m	Working capital	51	51	31	26	24	26	17	8	5	0
	Total debt	4	10	20	19	16	16	16	13	15	5
	Net debt	(46)	(40)	(16)	(9)	(9)	(11)	(3)	(6)	(3)	(6)
	Shareholders’ equity	73	64	56	51	47	43	36	29	23	25
Returns, %
Returns, %	ROA	(1.02)	(8.55)	(6.76)	(3.26)	(3.32)	(3.88)	(6.28)	(7.19)	(8.24)	(3.72)
	ROIC	(3.31)	(10.79)	(17.75)	(13.73)	(10.46)	(15.22)	(10.94)	(25.17)	(20.24)	(9.51)
	ROE	(1.26)	(11.64)	(11.65)	(6.63)	(6.82)	(7.84)	(14.18)	(19.25)	(25.02)	(12.05)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DERM Journey Medical Corporation	$144.7M	— (loss-making)	91.8×	+23.33% (above 0%: growing)	n/m	−84.08% (below 0%: shrinking)	66.81%	2.46%	Compare
ORGO Organogenesis	$142.8M	— (loss-making)	— (loss-making)	−56.68% (below 0%: shrinking)	n/m	+10.29% (above 0%: growing)	45.90%	(116.54%)	Compare
CRDL Cardiol Therapeutics Inc.	$138.8M	— (loss-making)	— (loss-making)	—	n/m	+10.61% (above 0%: growing)	0.00%	0.00%	Compare
OGI Organigram Global Inc.	$131.4M	2.0×	11.4×	+49.28% (above 0%: growing)	n/m	−192.32% (below 0%: shrinking)	39.16%	5.04%	Compare
BGM BGM Group Ltd.	$114.7M	144×	44.9×	−2.59% (below 0%: shrinking)	−85.71% (below 0%: shrinking)	+3.00% (above 0%: growing)	7.12%	0.00%	Compare
PROCF Sofgen Pharma S.A	$114.0M	0.1×	4.0×	+17.28% (above 0%: growing)	n/m	+231.11% (above 0%: growing)	56.09%	36.48%	Compare
CPIX Cumberland Pharmaceuticals Inc.	$113.0M	— (loss-making)	— (loss-making)	−56.28% (below 0%: shrinking)	n/m	−82.78% (below 0%: shrinking)	100.00%	(1,898.20%)
CLVR Clever Leaves Holdings Inc.	$96.5M	— (loss-making)	— (loss-making)	+5.36% (above 0%: growing)	n/m	+70.31% (above 0%: growing)	(7.46%)	(105.91%)	Compare
CTOR Citius Oncology, Inc.	$69.4M	— (loss-making)	—	—	n/m	0.00%	67.07%	(583.53%)	Compare
Median of peers	$123.0M	2.0×	28.2×	+11.32%	—	+6.65%	42.53%	0.00%

All 86 Drug Manufacturers Specialty & Generic stocks →

Cumberland Pharmaceuticals Inc. (CPIX) key facts

Cumberland Pharmaceuticals Inc. (CPIX) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CPIX traded at $7.18, a market capitalization of $113.0 million.
Return on equity was −12.1% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 0.65 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.